{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T21:30:33Z","timestamp":1780090233577,"version":"3.54.0"},"reference-count":36,"publisher":"BMJ","issue":"8","license":[{"start":{"date-parts":[[2023,8,7]],"date-time":"2023-08-07T00:00:00Z","timestamp":1691366400000},"content-version":"unspecified","delay-in-days":6,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"NIHR Applied Research Collaboration","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"name":"NIHR Advanced Fellowship","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"name":"Northern Ireland Clinical Research Network, Public Health Agency","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["PhD Programme for Primary Care Clinicians - 216421"],"award-info":[{"award-number":["PhD Programme for Primary Care Clinicians - 216421"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014013","name":"UK Research and Innovation","doi-asserted-by":"publisher","award":["UKRI\/NIHR - Grant number NIHR135366"],"award-info":[{"award-number":["UKRI\/NIHR - Grant number NIHR135366"]}],"id":[{"id":"10.13039\/100014013","id-type":"DOI","asserted-by":"publisher"}]},{"name":"NIHR Health Protection Research Unit on Health Care Associated Infections and Antimicrobial Resistance","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["COVID modelling grant, Grant number MR\/W015560\/1"],"award-info":[{"award-number":["COVID modelling grant, Grant number MR\/W015560\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"name":"NIHR Senior Investigator","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"name":"European Clinical Research Alliance on Infectious Diseases","award":["ECRAID-Prime. Grant number 101046109"],"award-info":[{"award-number":["ECRAID-Prime. Grant number 101046109"]}]},{"DOI":"10.13039\/501100023233","name":"NIHR Applied Research Collaboration Oxford and Thames Valley","doi-asserted-by":"crossref","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100023233","id-type":"DOI","asserted-by":"crossref"}]},{"name":"NIHR Community Healthcare Medtech and In-Vitro Diagnostics Co-operative","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"name":"NIHR Development and Skills Enhancement Award","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2023,7,3]]},"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>There is an urgent need to determine the safety, effectiveness and cost-effectiveness of novel antiviral treatments for COVID-19 in vaccinated patients in the community at increased risk of morbidity and mortality from COVID-19.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>PANORAMIC is a UK-wide, open-label, prospective, adaptive, multiarm platform, randomised clinical trial that evaluates antiviral treatments for COVID-19 in the community. A master protocol governs the addition of new antiviral treatments as they become available, and the introduction and cessation of existing interventions via interim analyses. The first two interventions to be evaluated are molnupiravir (Lagevrio) and nirmatrelvir\/ritonavir (Paxlovid). Eligibility criteria: community-dwelling within 5\u2009days of onset of symptomatic COVID-19 (confirmed by PCR or lateral flow test), and either (1) aged 50 years and over, or (2) aged 18\u201349 years with qualifying comorbidities. Registration occurs via the trial website and by telephone. Recruitment occurs remotely through the central trial team, or in person through clinical sites. Participants are randomised to receive either usual care or a trial drug plus usual care. Outcomes are collected via a participant-completed daily electronic symptom diary for 28 days post randomisation. Participants and\/or their Trial Partner are contacted by the research team after days 7, 14 and 28 if the diary is not completed, or if the participant is unable to access the diary. The primary efficacy endpoint is all-cause, non-elective hospitalisation and\/or death within 28 days of randomisation. Multiple prespecified interim analyses allow interventions to be stopped for futility or superiority based on prespecified decision criteria. A prospective economic evaluation is embedded within the trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>Ethical approval granted by South Central\u2013Berkshire REC number: 21\/SC\/0393; IRAS project ID: 1004274. Results will be presented to policymakers and at conferences, and published in peer-reviewed journals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"isrctn\" xlink:href=\"ISRCTN30448031\">ISRCTN30448031<\/jats:ext-link>\n                      ; EudraCT number: 2021-005748-31.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2022-069176","type":"journal-article","created":{"date-parts":[[2023,8,7]],"date-time":"2023-08-07T13:40:19Z","timestamp":1691415619000},"page":"e069176","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":25,"title":["Platform adaptive trial of novel antivirals for early treatment of COVID-19 In the community (PANORAMIC): protocol for a randomised, controlled, open-label, adaptive platform trial of community novel antiviral treatment of COVID-19 in people at increased risk of more severe disease"],"prefix":"10.1136","volume":"13","clinical-trial-number":[{"clinical-trial-number":"isrctn30448031","registry":"10.18810\/isrctn"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2963-4491","authenticated-orcid":false,"given":"Oghenekome","family":"Gbinigie","sequence":"first","affiliation":[{"name":"Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Ogburn","sequence":"additional","affiliation":[{"name":"Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Allen","sequence":"additional","affiliation":[{"name":"Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6072-1430","authenticated-orcid":false,"given":"Jienchi","family":"Dorward","sequence":"additional","affiliation":[{"name":"Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK"},{"name":"Centre for the Aids Programme of Research in South Africa (CAPRISA), University of KwaZulu\u2013Natal, Durban, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Dobson","sequence":"additional","affiliation":[{"name":"Nuffield Department of Medicine, Oxford Respiratory Trials Unit, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracie-Ann","family":"Madden","sequence":"additional","affiliation":[{"name":"Centre for Trials Research, Cardiff University, Cardiff, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ly-Mee","family":"Yu","sequence":"additional","affiliation":[{"name":"Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M","family":"Lowe","sequence":"additional","affiliation":[{"name":"University College London, Institute of Immunity and Transplantation, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Najib","family":"Rahman","sequence":"additional","affiliation":[{"name":"Nuffield Department of Medicine, Oxford Respiratory Trials Unit, Oxford, UK"},{"name":"NIHR Oxford Biomedical Research Centre, Oxford, UK"},{"name":"Chinese Academy of Medicine Oxford Institute, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stavros","family":"Petrou","sequence":"additional","affiliation":[{"name":"Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duncan","family":"Richards","sequence":"additional","affiliation":[{"name":"Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS), University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerenza","family":"Hood","sequence":"additional","affiliation":[{"name":"Centre for Trials Research, Cardiff University, Cardiff, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahendra","family":"Patel","sequence":"additional","affiliation":[{"name":"Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin R","family":"Saville","sequence":"additional","affiliation":[{"name":"Berry Consultants, Austin, Texas, USA"},{"name":"Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe","family":"Marion","sequence":"additional","affiliation":[{"name":"Berry Consultants, Austin, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Holmes","sequence":"additional","affiliation":[{"name":"Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5876-9363","authenticated-orcid":false,"given":"May Ee","family":"Png","sequence":"additional","affiliation":[{"name":"Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0852-627X","authenticated-orcid":false,"given":"Gail","family":"Hayward","sequence":"additional","affiliation":[{"name":"Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8309-568X","authenticated-orcid":false,"given":"Mark","family":"Lown","sequence":"additional","affiliation":[{"name":"Primary Care Research Centre, University of Southampton, Southampton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Harris","sequence":"additional","affiliation":[{"name":"Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhautesh","family":"Jani","sequence":"additional","affiliation":[{"name":"General Practice and Primary Care, School of Health and Wellbeing, MVLS, University of Glasgow, Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nigel","family":"Hart","sequence":"additional","affiliation":[{"name":"School of Medicine, Dentistry and Biomedical Sciences - Centre for Public Health, Queen's University Belfast, Belfast, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saye","family":"Khoo","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, University of Liverpool, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Rutter","sequence":"additional","affiliation":[{"name":"Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jem","family":"Chalk","sequence":"additional","affiliation":[{"name":"Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph F","family":"Standing","sequence":"additional","affiliation":[{"name":"Infection Inflammation and Immunology, UCL Great Ormond Street Institute of Child Health Population Policy and Practice, London, UK"},{"name":"Department of Pharmacy, Great Ormond Street Hospital for Children, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Breuer","sequence":"additional","affiliation":[{"name":"Infection Inflammation and Immunology, UCL Great Ormond Street Institute of Child Health Population Policy and Practice, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Layla","family":"Lavallee","sequence":"additional","affiliation":[{"name":"Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Hadley","sequence":"additional","affiliation":[{"name":"Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Cureton","sequence":"additional","affiliation":[{"name":"Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Benysek","sequence":"additional","affiliation":[{"name":"Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0619-1074","authenticated-orcid":false,"given":"Monique I","family":"Andersson","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8939-7312","authenticated-orcid":false,"given":"Nick","family":"Francis","sequence":"additional","affiliation":[{"name":"Primary Care Research Centre, University of Southampton, Southampton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas P B","family":"Thomas","sequence":"additional","affiliation":[{"name":"Windrush Medical Practice, Witney, UK"},{"name":"Thames Valley and South Midlands Clinical Research Network, National Institute for Health and Care Research, Oxford, UK"},{"name":"Royal College of General Practitioners, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Evans","sequence":"additional","affiliation":[{"name":"Faculty of Health and Life Sciences, University of Exeter, Exeter, UK"},{"name":"National Institute for Health Research Clinical Research Network, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"van Hecke","sequence":"additional","affiliation":[{"name":"Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona","family":"Koshkouei","sequence":"additional","affiliation":[{"name":"Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Coates","sequence":"additional","affiliation":[{"name":"Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Barrett","sequence":"additional","affiliation":[{"name":"Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clare","family":"Bateman","sequence":"additional","affiliation":[{"name":"Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Davies","sequence":"additional","affiliation":[{"name":"Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivy","family":"Raymundo-Wood","sequence":"additional","affiliation":[{"name":"Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Ustianowski","sequence":"additional","affiliation":[{"name":"Regional Infectious Diseases Unit, North Manchester General Hospital, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Nguyen-Van-Tam","sequence":"additional","affiliation":[{"name":"Lifespan and Population Health Unit, University of Nottingham School of Medicine, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Carson-Stevens","sequence":"additional","affiliation":[{"name":"Centre for Trials Research, Cardiff University, Cardiff, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Hobbs","sequence":"additional","affiliation":[{"name":"Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3664-1873","authenticated-orcid":false,"given":"Paul","family":"Little","sequence":"additional","affiliation":[{"name":"Primary Care Research Centre, University of Southampton, Southampton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0102-3453","authenticated-orcid":false,"given":"Christopher C","family":"Butler","sequence":"additional","affiliation":[{"name":"Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,8,7]]},"reference":[{"key":"2025121510003021000_13.8.e069176.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2109072"},{"key":"2025121510003021000_13.8.e069176.2","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1016\/j.cmi.2021.06.043","article-title":"Effectiveness of mRNA-BNT162b2, mRNA-1273, and Chadox1 nCoV-19 vaccines against COVID-19 in Healthcare workers: an observational study using surveillance data","volume":"27","author":"Paris","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"2025121510003021000_13.8.e069176.3","doi-asserted-by":"crossref","unstructured":"Pilishvili T , Gierke R , Fleming-Dutra KE , et al . Effectiveness of mRNA Covid-19 vaccine among U.S. health care personnel. N Engl J Med 2021;385. doi:10.1056\/NEJMoa2106599","DOI":"10.1056\/NEJMoa2106599"},{"key":"2025121510003021000_13.8.e069176.4","unstructured":"The Telegraph . Covid hospital admissions are surging again \u2013 is this the start of a new wave. 2022. Available: https:\/\/www.telegraph.co.uk\/global-health\/science-and-disease\/covid-hospital-admissions-surging-start-new-wave\/"},{"key":"2025121510003021000_13.8.e069176.5","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/S2213-2600(21)00310-6","article-title":"Doxycycline for community treatment of suspected COVID-19 in people at high risk of adverse outcomes in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial","volume":"9","author":"Butler","year":"2021","journal-title":"Lancet Respir Med"},{"key":"2025121510003021000_13.8.e069176.6","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(21)00461-X","article-title":"Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial","volume":"397","year":"2021","journal-title":"Lancet"},{"key":"2025121510003021000_13.8.e069176.7","unstructured":"Yu L-M , Bafadhel M , Dorward J , et al . Inhaled budesonide for COVID-19 in people at higher risk of adverse outcomes in the community: interim analyses from the PRINCIPLE trial. Medrxiv 2021."},{"key":"2025121510003021000_13.8.e069176.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2021436"},{"key":"2025121510003021000_13.8.e069176.9","doi-asserted-by":"publisher","DOI":"10.1038\/s41594-021-00657-8"},{"key":"2025121510003021000_13.8.e069176.10","unstructured":"Pfizer . Pfizer\u2019s novel COVID-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of phase 2\/3 EPIC-HR study. 2021. Available: https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizers-novel-covid-19-oral-antiviral-treatment-candidate"},{"key":"2025121510003021000_13.8.e069176.11","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.o1037","article-title":"Covid-19: what is the evidence for the antiviral paxlovid?","volume":"377","author":"Extance","year":"2022","journal-title":"BMJ"},{"key":"2025121510003021000_13.8.e069176.12","doi-asserted-by":"crossref","DOI":"10.1016\/j.dsx.2021.102329","article-title":"Molnupiravir in COVID-19: a systematic review of literature","volume":"15","author":"Singh","year":"2021","journal-title":"Diabetes Metab Syndr"},{"key":"2025121510003021000_13.8.e069176.13","first-page":"475","article-title":"Nirmatrelvir for nonhospitalized adults with COVID-19. reply","volume":"387","author":"Hammond","year":"2022","journal-title":"N Engl J Med"},{"key":"2025121510003021000_13.8.e069176.14","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.2316"},{"key":"2025121510003021000_13.8.e069176.15","doi-asserted-by":"publisher","DOI":"10.3399\/bjgp18X696569"},{"key":"2025121510003021000_13.8.e069176.16","unstructured":"National Institute for Health and Care Excellence . COVID-19 rapid guideline: managing COVID-19. 2021. Available: https:\/\/www.nice.org.uk\/guidance\/ng191"},{"key":"2025121510003021000_13.8.e069176.17","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1056\/NEJMra1510062","article-title":"Master protocols to study multiple therapies, multiple diseases, or both","volume":"377","author":"Woodcock","year":"2017","journal-title":"N Engl J Med"},{"key":"2025121510003021000_13.8.e069176.18","doi-asserted-by":"crossref","unstructured":"Butler C , Hobbs FDR , Gbinigie O , et al . Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial. SSRN Journal 2022. doi:10.2139\/ssrn.4237902","DOI":"10.2139\/ssrn.4237902"},{"key":"2025121510003021000_13.8.e069176.19","unstructured":"University of Oxford Primary Care Clinical Trials Unit . PANORAMIC trial 2021. Available: https:\/\/www.panoramictrial.org\/"},{"key":"2025121510003021000_13.8.e069176.20","unstructured":"UK Health Security Agency . People with symptoms of a respiratory infection including COVID-19. 2022. Available: https:\/\/www.gov.uk\/guidance\/people-with-symptoms-of-a-respiratory-infection-including-covid-19#what-to-do-if-you-have-a-positive-covid-19-test-result"},{"key":"2025121510003021000_13.8.e069176.21","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-011-9903-x"},{"key":"2025121510003021000_13.8.e069176.22","doi-asserted-by":"crossref","unstructured":"Moustgaard H , Clayton GL , Jones HE , et al . n.d. Impact of blinding on estimated treatment effects in randomised clinical trials: meta-epidemiological study. BMJ:l6802. doi:10.1136\/bmj.l6802","DOI":"10.1136\/bmj.l6802"},{"key":"2025121510003021000_13.8.e069176.23","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.l6228","article-title":"Fool\u2019s gold? Why blinded trials are not always best","volume":"368","author":"Anand","year":"2020","journal-title":"BMJ"},{"key":"2025121510003021000_13.8.e069176.24","unstructured":"National Institute for Health and Care Excellence . COVID-19 rapid guideline: managing COVID-19 [NG191]. 2021. Available: https:\/\/www.nice.org.uk\/guidance\/ng191"},{"key":"2025121510003021000_13.8.e069176.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2012.02.008"},{"key":"2025121510003021000_13.8.e069176.26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA2116044\/SUPPL_FILE\/NEJMOA2116044_DATA-SHARING.PDF"},{"key":"2025121510003021000_13.8.e069176.27","unstructured":"GOV.UK . Vaccinations in the United Kingdom 2022. Available: https:\/\/coronavirus.data.gov.uk\/details\/vaccinations"},{"key":"2025121510003021000_13.8.e069176.28","unstructured":"Merck . Merck and Ridgeback\u2019s investigational oral antiviral Molnupiravir reduced the risk of hospitalization or death by approximately 50 percent compared to placebo for patients with mild or moderate COVID-19 in positive interim analysis of phase 3 study 2021. Available: https:\/\/www.merck.com\/news\/merck-and-ridgebacks-investigational-oral-antiviral-molnupiravir-reduced-the-risk-of-hospitalization-or-death-by-approximately-50-percent-compared-to-placebo-for-patients-with-mild-or-moderat\/"},{"key":"2025121510003021000_13.8.e069176.29","doi-asserted-by":"crossref","unstructured":"Burki TK . Omicron variant and booster COVID-19 vaccines. Lancet Respir Med 2022;10. doi:10.1016\/S2213-2600(21)00559-2","DOI":"10.1016\/S2213-2600(21)00559-2"},{"key":"2025121510003021000_13.8.e069176.30","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-046799","article-title":"Platform randomised trial of interventions against COVID-19 in older peoPLE (PRINCIPLE): protocol for a randomised, controlled, open-label, adaptive platform, trial of community treatment of COVID-19 Syndromic illness in people at higher risk","volume":"11","author":"Hayward","year":"2021","journal-title":"BMJ Open"},{"key":"2025121510003021000_13.8.e069176.31","unstructured":"Office for National Statistics . 2011 census 2011. 2011. Available: https:\/\/www.nomisweb.co.uk\/census\/2011\/data_finder"},{"key":"2025121510003021000_13.8.e069176.32","unstructured":"National Institute for Health and Care Excellence . COVID-19 rapid guideline: managing the long-term effects of COVID-19. 2020. Available: https:\/\/www.nice.org.uk\/guidance\/NG188"},{"key":"2025121510003021000_13.8.e069176.33","doi-asserted-by":"crossref","unstructured":"Greenhalgh T , Knight M , A\u2019Court C , et al . Management of post-acute COVID-19 in primary care. BMJ:m3026. doi:10.1136\/bmj.m3026","DOI":"10.1136\/bmj.m3026"},{"key":"2025121510003021000_13.8.e069176.34","doi-asserted-by":"crossref","unstructured":"Cirulli ET , Schiabor Barrett KM , Riffle S , et al . Long-term COVID-19 symptoms in a large unselected population. Infectious Diseases (except HIV\/AIDS) 2020. doi:10.1101\/2020.10.07.20208702","DOI":"10.1101\/2020.10.07.20208702"},{"key":"2025121510003021000_13.8.e069176.35","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctim.2004.07.043"},{"key":"2025121510003021000_13.8.e069176.36","doi-asserted-by":"publisher","DOI":"10.3399\/BJGP.2022.0083"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2022-069176","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T18:00:41Z","timestamp":1765821641000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2022-069176"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":36,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,8,7]]},"published-print":{"date-parts":[[2023,8]]}},"alternative-id":["10.1136\/bmjopen-2022-069176"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2022-069176","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8]]}}}